Vasomune Therapeutics to Present on Vascular Leak in Combat-Relevant Injury at the 2026 Military Health System Research Symposium

Dr. Harold Kim will discuss Pegevongitide (AV-001), Vasomune’s lead candidate targeting vascular leak, an underlying pathology in injury and illness across casualty care TORONTO — Vasomune Therapeutics, Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing therapies that target vascular leak, today announced that Dr. Harold Kim, Chief Scientific Officer, will present at the 2026 Military Health […]

Dr. Harold Kim will discuss Pegevongitide (AV-001), Vasomune’s lead candidate targeting vascular leak, an underlying pathology in injury and illness across casualty care TORONTO — Vasomune Therapeutics, Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing therapies that target vascular leak, today announced that Dr. Harold Kim, Chief Scientific Officer, will present at the 2026 Military Health […]